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NEURAL REGENERATION RESEARCH

REVIEW

Targeting the mitochondrial permeability transition
pore in traumatic central nervous system injury
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Abstract

*Correspondence to:

The mitochondrion serves many functions in the central nervous system (CNS) and other organs beyond
the well-recognized role of adenosine triphosphate (ATP) production. This includes calcium-dependent
cell signaling, regulation of gene expression, synthesis and release of cytotoxic reactive oxygen species, and
the release of cytochrome c and other apoptotic cell death factors. Traumatic injury to the CNS results in
a rapid and, in some cases, sustained loss of mitochondrial function. One consequence of compromised
mitochondrial function is induction of the mitochondrial permeability transition (mPT) state due to
formation of the cyclosporine A sensitive permeability transition pore (mPTP). In this mini-review, we
summarize evidence supporting the involvement of the mPTP as a mediator of mitochondrial and cellular
demise following CNS traumatic injury and discuss the beneficial effects and limitations of the current experimental strategies targeting the mPTP.
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Introduction

The ability of cells in the central nervous system (CNS) to
survive and maintain a functional level of homeostasis following a traumatic injury depends on a number of critical
factors. At a relatively gross level, the type of insult (vascular,
structural, etc.) as well as the severity and proximity of cells to
the injury site are obvious factors. However, many pathophysiological events occur at the subcellular and molecular levels
that ultimately determine cellular demise or recovery. These
events have been well studied and include, but are not limited
to, glutamate excitotoxicity, Ca2+ overload, inflammation, free
radical mediated oxidative damage, and a loss of mitochondrial bioenergetics. Some of these secondary injury events are
intimately interconnected, which is one rationale for developing neuroprotective therapeutic strategies targeting cell death
signaling pathways at the molecular and cellular level.

The Mitochondrial Permeability Transition

Our research has focused on characterizing changes in mitochondrial function after spinal cord (SCI) and traumatic
brain (TBI) injuries (Sullivan et al., 2005; McEwen et al.,
2011). This is based on well-documented observations that
mitochondria play a critical role in determining cellular
fate, and compromised mitochondrial function is a prominent feature in both SCI and TBI. Under physiological
conditions, mitochondria exhibit a high transmembrane
potential generated by the proton pumping components of
the respiratory electron transport system. This transmembrane potential is a driving force in the phosphorylation of
adenosine diphosphate (ADP) and sequestering Ca2+ from
the cytosol. However, following SCI or TBI, mitochondria
rapidly become dysfunctional resulting in a loss of cytosolic
Ca2+ buffering capacity due to influx of massive pathophysiological levels of Ca2+ through glutamate receptor subtypes,
1338

free radical mediated oxidative damage to mitochondrial
complex proteins, and a subsequent compromise in bioenergetic capacity. This process becomes insidious as the loss
of energy production further reduces the ability of adenosine
triphosphate (ATP)-dependent Ca2+ channels to regulate
Ca2+ cytosolic levels. Prolonged Ca2+ overload can push mitochondria to the next pathophysiological stage- induction of
the mitochondrial permeability transition (mPT) state due to
mPT pore (mPTP) formation (Halestrap and Brenner, 2003).
The mPT state uncouples respiration from ATP production
and by this point recovery of mitochondrial function is limited at best. Cell survival is then compromised when sufficient
numbers of mitochondria undergo mPT. Given the importance of mitochondria in cellular function, inhibiting formation of the mPTP is a strategy for limiting cell death in both
SCI and TBI. In this perspective article, we summarize what
is known about the mPTP and discuss the possible pros and
cons of targeting the mPTP as a therapeutic strategy in CNS
injury.
The mPTP is a multiprotein mega-channel complex spanning both the inner and outer mitochondrial membranes,
essentially allowing for communication of small molecules
between the matrix and cytosol. The structural components
of the pore are not well understood and the subject of continuing debate. Initial studies suggested that the pore was
made up of the voltage-dependent anion channel (VDAC)
located on the outer mitochondrial membrane, the adenine
nucleotide translocator (ANT) on the inner mitochondrial
membrane, and cyclophilin-D (Cyp-D) in the matrix (Halestrap and Brenner, 2003). However, follow-up genetic deletion studies revealed that ANT and VDAC are not required
for mPTP formation, which may be explained, in part, by
the presence of different isoforms of these putative pore
components (Bernardi et al., 2015). Despite these observa-
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Table 1 Experimental studies testing the efficacy of CsA or NIM811 in the treatment of TBI
Study

TBI model/species Route

Dose/time

Outcome

Okonkwo et al. (1999)

IA/rat

i.t.

10 mg/kg CsA/30 minutes pre-injury

Okonkwo and
Povlishock (1999)
Büki et al. (1999)

IA/rat

i.t.

IA/rat

i.t.

Scheff and Sullivan
(1999)

CCI/rat and mice

i.p.

Sullivan et al. (1999)

CCI/rat

i.p.

Fukui et al. (2003)

CCI/rat

i.v.

Signoretti et al. (2004)

IA/rat

Gabbita et al. (2005)

CCI/rat

Turkoglu et al. (2010)

Contusion/rat

Colley et al. (2010)

FPI/rat

Sullivan et al. (2011)

CCI/rat

Decreased calpain-induced neurofilament
compaction and cytokeletal damage
10 mg/kg CsA/30 minutes pre-injury
Preserves mitochondrial morphology and prevents
axonal failure
10 mg/kg CsA/30 minutes post-injury
Decreases in neurofilament compaction, calpain
activity and amyloid precursor protein (APP)
accumulation
FK506: 40 or 20 mg/kg 5 minutes postImprovement in cortical sparing with CsA but not
injury + 24 hours post-injury. CsA: 20, 40, FK-506
or 150 mg/kg 5 minutes pre-injury
20 mg/kg CsA 15 minutes post-injury

Kilbaugh et al. (2011)

CCI/rat IA/piglet

Dixon et al. (2016)

FPI/CCI/PBBI/rat

Kulbe et al. (2017)

CCI/rat

20 or 35 mg/kg CsA 1 hour infusion at 30
minutes post-injury
i.t. and i.v. (1) i.t. 10 mg/kg 30 minutes post-injury
(2) i.v. 20 mg/kg 30 minutes post-injury
(3) i.v. 35 mg/kg 30 minutes post-injury
i.p.
20 mg/kg CsA 15 minutes + 24 hours postinjury
i.p./cortical 20 mg/kg CsA at time of injury 10 mg/kg
implant
CsA in microsphere formulation
i.p.
20 mg/kg CsA 15 minutes or 1 hour postinjury
i.p./pump 20 mg/kg CsA/i.p./1–8 hours post + pump
10 mg/kg/day
oral
NIM811: 5–40 mg/kg/15 minutes and 24
hours post-injury
NIM811: 10 mg/kg/15 minutes and 24
hours post-injury
i.p.
Rat: 20 mg/kg/CsA/15 minutes post-injury
Piglet: 20 mg/kg/CsA/5 minutes and 12
hours post-injury
i.v.
CsA:10 or 20 mg/kg 15 minutes and 24
hours post-injury
i.p.
20 mg/kg/CsA/15 minutes post-injury

Kulbe et al. (2018)

CCI/rat

i.p./pump

Readnower et al. (2011) CCI/rat

CsA: 20 mg/kg/CsA/15 minutes postinjury + pump: 10 mg/kg/day/3 days
Phenelzine (PZ): 10 mg/kg/CsA/15
minutes post-injury + pump:
10 mg/kg/day/3 days

Preservation of mitochondrial function and
decreased free radical production.
No significant change in brain water content
Adenosine triphosphate (ATP) levels restored in i.t.
and 35 mg/kg i.v. CsA administration groups
Significant decrease in hippocampal tau protein
degradation
Implantation of microsphere formulation improves
mitochondrial integrity
Significant neuroprotection for myelinated axons.
Neuroprotection was observed when CsA started
within 8 hours post-injury
NIM811 (10 mg/kg) improves mitochondrial
function, and reduces oxidative at 6 hours postinjury, and improves cognition 10 days post-injury
CsA improves mitochondrial function, preserves
cerebral blood flow, and limits neuropathology
No protective/functional effect of CsA on any
measure
Improve synaptic and non-synaptic mitochondrial
respiration
PZ and CsA together enhance neuroprotection

CCI: Controlled cortical impact; TBI: traumatic brain injury; CsA: cyclosporin A; FPI: fluid percussion injury; IA: inertial acceleration; i.p.:
intraperitoneal; i.t.: intrathecal; i.v.: intravenous; PBBI: penetrating ballistic-like brain injury.

tions, there is a general consensus that Cyp-D functions as a
major contributor to mPTP formation.

Inhibiting mPTP Formation in TBI and SCI

Cyclosporine A (CsA) is an immunosuppressant that inhibits mPT by binding to Cyp-D. It has been shown repeatedly
to be neuroprotective in TBI, although similar effects in
SCI remain controversial based on conflicting reports. This
differential efficacy of CsA in TBI versus SCI may be related to properties inherent to mitochondria in the respective
CNS regions. Moreover, it is difficult to examine a wide
dose range of CsA due to its potent side effects and potential toxicity. In fact, doses of CsA above 20 mg/kg were,
for the most part, ineffective in providing neuroprotection
following TBI. Given these caveats, our group started investigating the use of NIM811, a Cyp-D binding CsA derivate
lacking any immunosuppressive properties and having relatively minimal toxicity (Waldmeier et al., 2002). Our early

studies provided evidence that NIM811 reduces oxidative
damage while improving mitochondrial function and tissue
sparing following TBI or SCI (McEwen et al., 2007; Mbye
et al., 2008). The outcome of these studies provided strong
evidence that NIM811 and CsA exhibited neuroprotective
effects by inhibiting mPTP formation. A recent report by
our group revealed a dose dependent effect of post-injury
NIM811 treatment in experimental SCI (Springer et al.,
2018). Interestingly, we observed that a low dose of NIM811
significantly improved locomotor recovery, while higher
doses significantly increased tissue sparing and reflexive
bladder control but not recovery of locomotor function. The
reasons for these dose-related differences are not clear at
this time, although it can be suggested that conducting a follow-up study examining additional doses in the range used
in this study might prove revealing.
As stated above, there is strong evidence that targeting the
mPTP has therapeutic potential in the treatment of TBI and
1339
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Table 2 Experimental studies testing the efficacy of CsA or NIM811 in the treatment of traumatic SCI
Study
Diaz-Ruiz et al.
(1999)
Rabchevsky et al.
(2001)
Ibarra et al.
(2003)
McEwen et al.
(2007)
Ibarra et al.
(2007)

SCI model/
species

Route

Contusion/rat i.p.
Contusion/rat i.p./pump
Compression/ Oral, i.p.
rat
Contusion/rat i.p.
Transection/
rat

Oral

Ravikumar et al.
(2007)

Contusion/rat Oral

Springer et al.
(2018)

Contusion/rat Oral

Chen et al. (2018) Contusion/rat Pump

Dose/time

Outcome

CsA: 2.5 mg/kg every 12 hours for 1 or 3 days CsA significantly decreased lipid peroxidation and
improved motor scores on the Tarlov scale.
CsA: 20 mg/kg/15 minutes post-injury + 2.5 CsA had no effect on any outcome measure.
mg/kg/day pump
CsA: 5 mg/kg/12 hours starting 48 hours
CsA inhibited demyelination and death of descending
before injury until study endpoint. 2.5 mg/kg rubrospinal tract axons, and also improved motor recovery
i.p. first 3 days after injury.
(BBB scale).
NIM811: 40 mg/kg/15 minutes pre-injury
NIM811 significantly improved mitochondrial function
and decreased mitochondrial free radical production.
CsA: 2.5 mg/kg 6 hours and 12 hours post
CsA increased axonal growth and GAP-43 expression, but
followed by 5 mg/kg daily until study endpoint axons were not functional and there was no behavioral
recovery.
NIM811:20 mg/kg/1, 12, and 24 hours post- NIM811 significantly reduced cytochrome c and
injury
fragmented DNA, and increased spared gray and white
matter.
NIM811: 10, 20, or 40 mg/kg at 1, 12, and 24 NIM811 significantly improved open field locomotor
hours post-injury
performance (10 mg/kg). 20 and 40 mg/kg significantly
improved return of reflexive bladder control and tissue
sparing.
CsA: 4 mg/kg/daily for 7, 14, or 21 days
CsA decreased apoptosis and cytokine levels. Preserves
mitochondrial morphology and prevents diffuse axonal
injury.

SCI: Spinal cord injury; CsA: cyclosporin A; i.p.: intraperitoneal; BBB: Basso Beattie Bresnahan.

SCI and numerous studies have examined this hypothesis
with mixed results. We conducted a PubMed search to identify published studies investigating CsA or NIM811 in either
TBI or SCI and the results of this search are summarized in
Tables 1 and 2, respectively. What is clear from this analysis
is that the many labs found CsA or NIM811 to be effective
in the treatment of various TBI-related outcomes across a
range of doses, routes of administration and injury models.
NIM811 was reported to be effective in one TBI study while
all but two studies (see Fukui et al. (2003) and Dixon et al.
(2016) in Table 1) reported structural, physiological, or
functional efficacy with CsA treatment. It is interesting to
point out that these two negative outcome studies used an
intravenous route of delivery, while the positive outcome
studies employed intrathecal, subcutaneous or intraperitoneal routes of administration. Given the pharmacokinetics,
clearance rates, etc., associated with different routes of administration, it is possible to speculate that an intravenous
route may not be optimal. One of these studies (Fukui et al.,
2003) recommended that another route of administration
be considered as there was no effect of intravenous CsA
administration at least in terms of reducing brain edema.
In addition, we have avoided an intravenous route of administration in our TBI and SCI studies due to the relative
toxicity of the vehicle. However, the results of a prospective
randomized clinical trial indicate a good safety profile when
using intravenous CsA administration in severe TBI patients
(Mazzeo et al., 2009).
CsA treatment in compression, contusion, or transection models of SCI has been reported to be either effective
or ineffective in promoting functional recovery and tissue
sparing (see Table 2). For example, work from Ibarra and
colleagues report that CsA reduces lipid peroxidation, increases survival of rubrospinal tract axons, and improves
1340

functional recovery, while Rabchevsky et al. (2001) report
no effect of CsA treatment on any outcome measure including functional recovery, tissue sparing. The reason for
the discrepancies is not entirely clear, but may be related to
differences in the injury models, injury severities, dosing,
and routes of administration. We also demonstrated that the
Cyp-D and oxidative stress levels are higher in uninjured
spinal cord relative to cortex, and that it takes a higher dose
of CsA to inhibit mPTP in mitochondria isolated from spinal cord compared to cortex (Sullivan et al., 2004). This is
an important observation as our recent and previous studies
have focused exclusively on NIM811, which can be used
at higher doses than CsA. These studies demonstrate that
NIM811 treatment increases mitochondrial function, spinal
cord tissue sparing, and functional recovery in a contusion
injury model (Table 2).

Future Considerations

One caveat of comparing CsA efficacy is the fact that many
negative reports go unpublished making it difficult to ascertain the true impact of CsA treatment in TBI and SCI.
Regardless, given the detrimental side effects of CsA and
its vehicle, as well as its immunosuppressive properties, we
support the idea of targeting mPTP in both TBI and SCI
using reformulated CsA and non-immunosuppressive CsA
derivatives such as NIM811. However, some effort should
go into understanding the impact of targeting mPTP formation in cells that are significantly compromised and may not
survive without intervention. There is evidence that mitochondrial dysfunction persists well beyond the acute stages
following TBI and SCI, and it is not clear whether rescuing
compromised mitochondria in minimally functioning cells
is beneficial. For example, the benefit of CsA administration
seems to follow an inverted U-shape highlighting the need
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for robust therapeutic window data in preclinical studies. It
also is not clear what cellular energy demands are placed on
surrounding cells in order to maintain minimally functioning
cells that might die off in the absence of mPTP targeted drugs.
Finally, the current mPTP drugs do not exhibit any cell specificity, which might prove detrimental if treatment promotes
survival and life span of pro-inflammatory and destructive
microglia, neutrophils, macrophages, and astrocytes.
In conclusion, there is compelling evidence that targeting
the mPTP with CsA or NIM811 limits secondary injury and
promotes functional recovery after TBI and SCI. Future
studies examining the therapeutic potential of this strategy
will rely, in part, on 1) identification of other CsA analogues
or other compounds that selectively target the mPTP, 2)
replication of existing studies using identical methodologies,
and 3) examination of mPTP targeted drugs in other species
and other injury models in which mPTP is known to occur.
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